Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Endocrine 3Other hematologic neoplasm 2Gynecologic 2NET 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Brain Neoplasms 264Glioblastoma 245Glioma 187Neuroblastoma 83Neoplasms 58Central Nervous System Neoplasms 53Astrocytoma 53Medulloblastoma 45Breast Neoplasms 42Sarcoma 38Melanoma 38Carcinoma, Non-Small-Cell Lung 37Neurofibromatosis 1 36Meningioma 35Ependymoma 35Lung Neoplasms 34Osteosarcoma 29Rhabdomyosarcoma 28Diffuse Intrinsic Pontine Glioma 27Sarcoma, Ewing 26Recurrence 26Rhabdoid Tumor 25Neoplasm Metastasis 25Oligodendroglioma 22Wilms Tumor 21Gliosarcoma 21Pancreatic Neoplasms 20Pheochromocytoma 19Hepatoblastoma 19Thyroid Neoplasms 18

Interventions

lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension × CNS × 90 days × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡